Table 4.
Log EC50 and Emax values of concentration-response curves in aorta and left anterior descending coronary artery (LAD)
| Dose (mg/kg bw/week) | Log EC50 (M) | Emax (%) | |||||
|---|---|---|---|---|---|---|---|
| Aorta | LAD proximal | LAD distal | Aorta | LAD proximal | LAD distal | ||
| ACh | |||||||
| Control | 0 | −5.8 (−6.1 to −5.4) | −7.3 (−7.4 to − 7.2) | −7.5 (− 7.7 to − 7.3) | 38.9 (34.6–46.0) | 98.2 (94.5–102.0) | 93.3 (87.1–100.4) |
| E171 | 50 | − 6.0 (− 6.7 to − 2.3) | − 7.5 (− 7.6 to − 7.4) | −7.6 (− 7.7 to − 7.4) | 43.1 (35.2–131.6) | 101.1 (97.6–104.7) | 98.0 (92.3–104.5) |
| 500 | −6.1 (− 6.6 to − 5.1) | −7.2 (− 7.4 to − 7.1) | −7.6 (− 7.9 to − 7.3) | 49.5 (42.4–75.0) | 101.4 (96.1–107.4) | 112.0* (101.9–124.7) | |
| E153 | 0.64 | −5.9 (− 6.2 to − 5.5) | −7.1 (− 7.2 to − 6.9) | −7.4 (− 7.6 to − 7.3) | 34.6 (30.7–41.4) | 111.1* (104.3–119.1) | 101.4 (95.9–107.6) |
| 6.4 | −5.9 (− 6.4 to − 4.3) | −7.5 (− 8.0 to − 7.2) | −7.4 (− 7.6 to − 7.2) | 40.2 (33.2–74.1) | 98.9 (88.5–116.1) | 111.5* (103.5–120.6) | |
| NTG | |||||||
| Control | 0 | −7.5 (− 7.6 to − 7.4) | − 5.4 (− 6.1 to − 3.0) | −6.7 (− 7.1 to − 6.1) | 91.0 (87.2–95.6) | 153.1 (115.7–365.2) | 111.1 (96.8–144.3) |
| E171 | 50 | −7.5 (− 7.7 to − 7.2) | − 5.2 (− 6.0 to − 0.1) | −5.9 (− 6.4 to − 4.7) | 89.0 (82.2–99.3) | 166.2 (118.7–902.1) | 143.0 (117.2–226.7) |
| 500 | −7.8* (− 8.0 to − 7.7) | − 6.6 (− 7.3 to 2.6) | − 6.2 (− 6.7 to − 4.9) | 94.1 (90.5–98.2) | 125.8 (98.9–1086.0) | 115.3 (94.8–188.8) | |
| E153 | 0.64 | −7.8 (− 8.0 to − 7.6) | − 5.0 (− 5.9 to 0.8) | −6.3 (− 6.9 to − 6.1) | 90.2 (85.1–96.8) | 176.0 (122.9–1208.0) | 126.4 (98.3–480.6) |
| 6.4 | −7.7 (− 7.9 to − 7.5) | −6.2 (− 6.6 to − 5.5) | −6.2 (− 7.0 to 17.1) | 89.2 (83.8–96.3) | 129.5 (111.4–171.2) | 142.5 (107.8–26,498.0) | |
| 5-HT | |||||||
| Control | 0 | −5.2 (− 5.3 to − 5.0) | − 6.2 (− 6.4 to − 6.0) | − 6.0 (− 6.2 to − 5.9) | 125.8 (117.7–135.4) | 158.9 (147.5–171.5) | 112.2 (104.4–120.9) |
| E171 | 50 | −5.1 (− 5.2 to − 5.0) | −6.3 (− 6.4 to − 6.1) | −6.2 (− 6.4 to − 6.0) | 128.4 (120.7–137.8) | 152.2 (144.1–160.7) | 155.4* (141.5–171.3) |
| 500 | −5.2 (− 5.4 to − 5.0) | −6.2 (− 6.6 to − 5.8) | −6.1 (− 6.3 to − 5.8) | 113.9 (100.4–132.5) | 126.9 (111.5–149.5) | 113.7 (102.6–126.7) | |
| E153 | 0.64 | −5.0 (− 5.1 to − 4.9) | − 6.3 (− 6.6 to − 5.9) | −6.2 (− 6.4 to − 5.9) | 130.8 (122.2–141.1) | 172.4 (152.6–201.3) | 115.1 (102.6–128.7) |
| 6.4 | −5.1 (− 5.3 to − 5.0) | − 6.3 (− 6.6 to − 6.0) | 6.1 (− 6.3 to − 5.9) | 123.5 (115.2–133.6) | 132.8 (119.4–148.9) | 112.2 (103.9–121.9) | |
The concentration-response curves were performed for acetylcholine (ACh), nitroglycerine (NTG) and 5-hydroxytryptamine (5-HT) on the aorta and coronary arteries from rats exposed intragastrically to E171 or E153 once a week for 10 weeks. The data are presented as mean and 95% CI. The number of animals in each group varied; specified in the concentration-response curves (Figs. 6, 7 and 8). An asterisk (*) denotes statistically significant effects when compared to the effect in the control group (P < 0.05)